Almost 30,000 people in England with chronic obstructive pulmonary disease (COPD) could soon have access to a biologic treatment, Sanofi and Regeneron's Dupixent, after it was recommended for use by ...
Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk when they launched phase 3 ...
Dupixent, the world's first targeted biological agent for atopic dermatitis treatment, was recently approved by China's National Medical Products Administration to be used for children as young as six ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results